Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KARIVA vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits gonadotropin release, suppressing ovulation, altering cervical mucus to impede sperm penetration, and changing endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Management of heavy menstrual bleeding (off-label),Treatment of acne (off-label),Treatment of dysmenorrhea (off-label),Endometriosis pain relief (off-label)
Prevention of pregnancy (FDA-approved)
One tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is 4.5 hours; in renal impairment (Cr Cl <30 m L/min), half-life may extend to 8-10 hours, requiring dose adjustment.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Hepatic via CYP3A4 for both ethinyl estradiol and levonorgestrel; undergoes conjugation (glucuronidation and sulfation). Ethinyl estradiol also undergoes oxidative metabolism. Levonorgestrel is reduced and conjugated.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Approximately 55% renal (30% as unchanged drug, 25% as metabolites) and 45% fecal (via biliary elimination).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
99% bound to albumin; minor binding to alpha-1-acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
0.27 L/kg (range 0.2-0.5 L/kg); distribution into total body water and highly perfused tissues.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 85-90% (complete absorption; first-pass metabolism reduces systemic availability to ~75% in elderly).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment or end-stage renal disease; use with caution and monitor for adverse effects.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute hepatic disease or severe hepatic impairment (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), no specific dosage adjustment is established; use with caution and monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (one tablet daily as per 21/7 regimen).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. No specific elderly considerations as the drug is not used in this population.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination hormonal contraceptive use. Risk increases with age (>35 years) and with number of cigarettes smoked. Women over 35 who smoke should not use Kariva.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (e.g., DVT, PE, MI, stroke),Hepatic neoplasia (benign and malignant) reported,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Retinal thrombosis (discontinue if vision loss or proptosis occurs),Depression,Bleeding irregularities (breakthrough bleeding, amenorrhea),Liver function abnormalities (discontinue if jaundice develops),Chloasma (may persist)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy (known or suspected),Active liver disease or benign/malignant liver tumors,Severe hypertension,Diabetes with vascular involvement,Migraine with focal aura (especially if over 35 years),Hypersensitivity to any component,Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir ± dasabuvir
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions; however, grapefruit juice may increase estrogen levels (theoretical). Avoid high-fat meals as they may affect absorption. Consistent intake with food can reduce nausea.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. Contraindicated in pregnancy due to known teratogenicity. First trimester exposure associated with cardiovascular defects, limb reduction defects, and neural tube defects. Second and third trimester use linked to fetal hepatic adenoma and female pseudohermaphroditism (due to progestogenic activity).
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted into breast milk. M/P ratio not established. Avoid breastfeeding due to potential adverse effects in nursing infants.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable; contraindicated in pregnancy. No dose adjustment recommended for use in non-pregnant women.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Kariva (desogestrel/ethinyl estradiol) is a monophasic oral contraceptive. It is effective for contraception but also used for acne and menstrual regulation. Breakthrough bleeding is common in first 3 cycles. Counsel on missed pill protocol. Check for contraindications: smoking >35, history of DVT/PE, migraine with aura, liver disease, breast cancer. Note that antibiotics (rifampin, griseofulvin) and anticonvulsants may reduce efficacy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, preferably after an evening meal.,If you miss one pill, take it as soon as remembered; if missed two or more, use backup contraception.,Common side effects include nausea, breast tenderness, and spotting; these usually improve after 3 months.,Avoid smoking while taking this medication, especially if over 35 years old.,Inform your doctor before starting any new medications, including antibiotics and herbal supplements.,Kariva may decrease milk supply; not recommended if breastfeeding.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KARIVA vs AFIRMELLE, answered by our medical review team.
KARIVA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits gonadotropin release, suppressing ovulation, altering cervical mucus to impede sperm penetration, and changing endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KARIVA and AFIRMELLE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KARIVA is: One tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KARIVA and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KARIVA is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to known teratogenicity. First trimester exposure associated with cardiovascular defects, limb reduction defects, and neu. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.